Date: Sunday, June 3, 2018
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall 4EF
Purpose: There is an elevated risk of acute rejection in HIV+ renal transplant recipients and continued evaluation of the most appropriate induction therapy remains. Use of an IL-2 inhibitor may avoid the potential risks of lymphocyte depletion on accelerated HIV disease progression and infection in the HIV+ recipient. The objective of this study is to assess the role of basiliximab on acute rejection, patient, and allograft survival in HIV+ recipients compared to a matched cohort of HIV- recipients.
Methods: This is a single center, retrospective study of adult HIV+ renal transplant recipients, matched 1:2 to an HIV- cohort, transplanted from 2006 to 2016 who received basiliximab induction. Matching was based on date of transplant within 1 year and race. BPAR, patient and allograft survival were evaluated at 1 and 3 years post-transplant.
Results: A total of 87 patients were included. A trend towards increased biopsy proven acute rejection at 3 years was observed in the HIV+ group (Figure 1). Measured GFR at 1 year was significantly higher in HIV- patients. There was no difference between patient or graft survival at 1 year.
Conclusions: Similar rejection, graft, and survival outcomes were observed when non-lymphocyte depleting induction and CNI-based maintenance therapy was used in an HIV+ and HIV- matched renal transplant cohort.
|Age (year±SD)||47 ± 9||57 ± 9||<0.01|
|Male gender||27 (93%)||34 (59%)||<0.01|
|Black||22 (76%)||40 (69%)||0.67|
|Dialysis prior to transplant||28 (96%)||41 (71%)||<0.01|
|HCV+||9 (7%)||23 (38%)||<0.01|
|Deceased donor||21 (72%)||35 (60%)||0.35|
|DGF||7 (24%)||19 (33%)||0.62|
|GFR at 1 year||37 ± 14||44 ± 14||<0.01|
|Patient survival at 1 year||28 (96%)||57 (98%)||0.61|
|Graft survival at 1 year||27 (93%)||55 (95%)||0.75|
CITATION INFORMATION: Schulte J., Richardson C., Stosor V., Cunningham K., D'Agostino C., Kane C. Basiliximab Induction in HIV-Positive Renal Transplant Recipients Compared to an HIV-Negative Cohort Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Schulte J, Richardson C, Stosor V, Cunningham K, D'Agostino C, Kane C. Basiliximab Induction in HIV-Positive Renal Transplant Recipients Compared to an HIV-Negative Cohort [abstract]. https://atcmeetingabstracts.com/abstract/basiliximab-induction-in-hiv-positive-renal-transplant-recipients-compared-to-an-hiv-negative-cohort/. Accessed April 7, 2020.
« Back to 2018 American Transplant Congress